非奈利酮用于射血分数轻度降低或保留的心力衰竭
FINEARTS-HF 为国际、双盲试验,纳入射血分数≥40%的心力衰竭患者,1:1 随机接受非奈利酮(最大剂量 20 mg 或 40 mg 每日一次)或匹配安慰剂,并联合常规治疗;主要终点为总心力衰竭恶化事件(首次或复发性计划外住院或紧急就诊)与心血管死亡的复合终点。中位随访 32 个月,非奈利酮组 3003 例中 624 例发生 1083 次主要终点事件,安慰剂组 2998 例中 719 例发生 1283 次(率比 0.84;95%CI 0.74–0.95;P=0.007)。非奈利酮显著减少总心力衰竭恶化事件(842 vs 1024;率比 0.82;95%CI 0.71–0.94;P=0.006),心血管死亡百分比 8.1% vs 8.7%(HR 0.93;95%CI 0.78–1.11)。非奈利酮与高钾血症风险增加及低钾血症风险降低相关。
要点
- 射血分数≥40%心力衰竭患者,非奈利酮(最大剂量 20 mg 或 40 mg 每日一次)较安慰剂显著降低主要复合终点(率比 0.84;95%CI 0.74–0.95;P=0.007)。
- 非奈利酮组总心力衰竭恶化事件 842 次 vs 安慰剂组 1024 次(率比 0.82;95%CI 0.71–0.94;P=0.006)。
- 心血管死亡百分比非奈利酮组 8.1% vs 安慰剂组 8.7%(HR 0.93;95%CI 0.78–1.11),差异未达统计学显著。
- 非奈利酮与高钾血症风险增加相关,与低钾血症风险降低相关。
- 中位随访 32 个月,主要终点事件在非奈利酮组 3003 例中 624 例发生 1083 次,安慰剂组 2998 例中 719 例发生 1283 次。
适用人群与场景
- 心力衰竭且左心室射血分数≥40%的患者(射血分数轻度降低或保留),国际多中心试验人群,在常规治疗基础上加用研究药物。
诊断标准与关键阈值
- 左心室射血分数≥40%为纳入标准。
- 主要终点事件定义为首次或复发性计划外住院或紧急就诊用于心力衰竭。
处置流程与药物剂量
- 非奈利酮最大剂量 20 mg 或 40 mg 每日一次口服,联合常规治疗;对照组为匹配安慰剂。
研究设计与关键结果
- 国际、双盲试验,1:1 随机分配射血分数≥40%的心力衰竭患者至非奈利酮组(3003 例)或安慰剂组(2998 例),中位随访 32 个月。
- 主要复合终点(总心力衰竭恶化事件与心血管死亡):非奈利酮组 624 例发生 1083 次事件 vs 安慰剂组 719 例发生 1283 次事件,率比 0.84(95%CI 0.74–0.95;P=0.007)。
- 总心力衰竭恶化事件:非奈利酮组 842 次 vs 安慰剂组 1024 次,率比 0.82(95%CI 0.71–0.94;P=0.006)。
- 心血管死亡百分比:非奈利酮组 8.1% vs 安慰剂组 8.7%,HR 0.93(95%CI 0.78–1.11)。
- 安全性:非奈利酮与高钾血症风险增加相关,与低钾血症风险降低相关。
证据类型、等级与局限
- 证据类型:国际、双盲、随机、安慰剂对照试验(FINEARTS-HF,ClinicalTrials.gov NCT04435626)。
- 由拜耳(Bayer)资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于射血分数≥40%的心力衰竭患者,作者结论认为非奈利酮较安慰剂显著降低总心力衰竭恶化事件与心血管死亡复合终点发生率。
- 使用非奈利酮时需注意高钾血症风险增加,低钾血症风险降低。
指南或共识出处
- FINEARTS-HF 试验,ClinicalTrials.gov 编号 NCT04435626,发表于 N Engl J Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.
METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed.
RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia.
CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
参考来源
- Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024. PMID: 39225278. doi:10.1056/NEJMoa2407107
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。